Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar;51(1):22-31.
doi: 10.1007/s13139-016-0411-3. Epub 2016 Apr 7.

FDG Whole-Body PET/MRI in Oncology: a Systematic Review

Hyun Woo Kwon  1 , Ann-Katharina Becker  2 , Jin Mo Goo  3 , Gi Jeong Cheon  4
Affiliations
Review

FDG Whole-Body PET/MRI in Oncology: a Systematic Review

Hyun Woo Kwon et al. Nucl Med Mol Imaging. 2017 Mar.

Abstract

The recent advance in hybrid imaging techniques enables offering simultaneous positron emission tomography (PET)/magnetic resonance imaging (MRI) in various clinical fields. 18F-fluorodeoxyglucose (FDG) PET has been widely used for diagnosis and evaluation of oncologic patients. The growing evidence from research and clinical experiences demonstrated that PET/MRI with FDG can provide comparable or superior diagnostic performance more than conventional radiological imaging such as computed tomography (CT), MRI or PET/CT in various cancers. Combined analysis using structural information and functional/molecular information of tumors can draw additional diagnostic information based on PET/MRI. Further studies including determination of the diagnostic efficacy, optimizing the examination protocol, and analysis of the hybrid imaging results is necessary for extending the FDG PET/MRI application in clinical oncology.

Keywords: FDG; Oncology; PET/MRI; Positron emission tomography/magnetic resonance imaging.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

Hyun Woo Kwon, Ann-Katharina Becker, Jin Mo Goo, and Gi Jeong Cheon declare that they have no conflict of interest.

Ethical Statement

This paper dose not contains any patient information and only includes a representative case originated from previous research approved by the Institutional Review Board of our hospital (1306-055-495). The manuscript has not been published before, or is not under consideration for publication anywhere else. This manuscript has been approved by all co-authors.

Figures

Fig. 1
Fig. 1
The study-selection protocol in this review. PICTS strategy demonstrates the Eligible patients, Index test, Comparator/reference test, Target condition and Study design; FDG 18F-fluorodeoxyglucose, PET positron emission tomography, MRI magnetic resonance imaging, CT computed tomography, RCT randomized controlled trial
Fig. 2
Fig. 2
(a) The maximal intensity projection (MIP) image of whole-body PET in patient with right tonsil cancer. The post-contrast computed tomography (CT) (b) and T1-weighted MR image (c) showed moderately enhanced cervical lymph nodes in bilateral neck. On the contrary, PET image (d) and fusion image (e) showed focal hypermetabolism in right cervical lymph node (red arrow). This lymph node was pathologically proven as a metastatic node
Fig. 3
Fig. 3
This patient with treated breast cancer underwent PET/MRI examination for evaluation of hepatic metastases (a MIP image of PET). (b) Delayed-phase (10 min) of post-contrast MR image revealed additional hepatic metastasis lesion (white arrow) without hypermetabolism (c PET). Furthermore, whole-body PET/MR imaging enabled us to detect asymptomatic brain metastasis (red arrow) (d apparent diffusion coefficient image; e PET)
See this image and copyright information in PMC

References

    1. Rasmussen JH, Fischer BM, Aznar MC, Hansen AE, Vogelius IR, Lofgren J, et al. Reproducibility of (18)F-FDG PET uptake measurements in head and neck squamous cell carcinoma on both PET/CT and PET/MR. Br J Radiol. 2015;88:20140655. doi: 10.1259/bjr.20140655. - DOI - PMC - PubMed
    1. Wiesmuller M, Quick HH, Navalpakkam B, Lell MM, Uder M, Ritt P, et al. Comparison of lesion detection and quantitation of tracer uptake between PET from a simultaneously acquiring whole-body PET/MR hybrid scanner and PET from PET/CT. Eur J Nucl Med Mol Imaging. 2013;40:12–21. doi: 10.1007/s00259-012-2249-y. - DOI - PubMed
    1. Quick HH, von Gall C, Zeilinger M, Wiesmuller M, Braun H, Ziegler S, et al. Integrated whole-body PET/MR hybrid imaging: clinical experience. Invest Radiol. 2013;48:280–9. doi: 10.1097/RLI.0b013e3182845a08. - DOI - PubMed
    1. Pace L, Nicolai E, Luongo A, Aiello M, Catalano OA, Soricelli A, et al. Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues. Eur J Radiol. 2014;83:289–96. doi: 10.1016/j.ejrad.2013.11.002. - DOI - PubMed
    1. Schuler MK, Platzek I, Beuthien-Baumann B, Fenchel M, Ehninger G, van den Hoff J. (18)F-FDG PET/MRI for therapy response assessment in sarcoma: comparison of PET and MR imaging results. Clin Imaging. 2015;39:866–70. doi: 10.1016/j.clinimag.2015.05.014. - DOI - PubMed

LinkOut - more resources